Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Epigenome-wide association study of incident type 2 diabetes in a British population: EPIC-Norfolk study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lean women with polycystic ovary syndrome and insulin resistance have normal incretin effect, which is unaffected by metformin therapy

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in HNF1A-diabetes

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH 2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH 2 During 4-h oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH 2 (800 pmol/kg/min) plus exendin(9-39)NH 2 (0-20 min: 1,000 pmol/kg/min; 20-240 min: 450 pmol/kg/min), B) GIP(3-30)NH 2, C) exendin(9-39)NH 2, and D) saline, respectively. Glucose excursions were significantly higher during A than during B, C, and D, while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide/glucose ratio) was reduced by 37 ± 16% (A), 30 ± 17% (B), and 8.6 ± 16% (C) compared with D (mean ± SD). A and C resulted in higher glucagon levels and faster gastric emptying. In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals.

OriginalsprogEngelsk
TidsskriftDiabetes
Vol/bind68
Udgave nummer5
Sider (fra-til)906-917
Antal sider12
ISSN0012-1797
DOI
StatusUdgivet - maj 2019

ID: 56362391